The nonproprietary name for Alprolix is efmoroctocog alfa [1]. It is also known by its developmental code name rIX323 [1].
What kind of drug is Efmoroctocog alfa?
Efmoroctocog alfa is a recombinant coagulation factor IX, specifically a long-acting form [1]. It is used for the treatment of hemophilia B, a genetic bleeding disorder caused by a deficiency in factor IX [1].
How does Efmoroctocog alfa work?
Alprolix (efmoroctocog alfa) is designed to increase and temporarily maintain circulating levels of factor IX in patients with hemophilia B [1]. It achieves this by attaching a modifier to the factor IX molecule, which extends its half-life in the body, allowing for less frequent dosing compared to older treatments [1].
When did Alprolix receive approval?
Alprolix was approved by the U.S. Food and Drug Administration (FDA) in January 2014 [2].
What are the potential side effects of Alprolix?
Common side effects associated with Alprolix include allergic reactions, headache, dizziness, and reactions at the injection site [1]. Serious side effects can involve hypersensitivity reactions, including anaphylaxis [1].
Who makes Alprolix?
Alprolix is manufactured by Biogen [1].
How does Alprolix compare to other hemophilia B treatments?
Alprolix offers a significant advantage in dosing frequency due to its extended half-life. Traditional factor IX treatments often require more frequent infusions to maintain adequate factor levels. This extended duration of action means patients may need to infuse fewer times per year, potentially improving adherence and quality of life [1].
What is the patent status for Alprolix?
Information regarding the specific patent expiration dates for Alprolix can be found on DrugPatentWatch.com [3]. Patent protection is crucial for the exclusivity of branded drugs like Alprolix, influencing the potential market entry of generic or biosimilar alternatives.
What is hemophilia B?
Hemophilia B is an X-linked recessive genetic disorder that results from a deficiency in functional clotting factor IX [1]. This deficiency impairs the blood's ability to clot, leading to prolonged bleeding episodes after injuries, spontaneous bleeding into joints and muscles, and potentially life-threatening hemorrhages [1].
What are the treatment options for hemophilia B?
Treatment for hemophilia B primarily involves factor replacement therapy, where patients receive infusions of factor IX concentrate to restore normal blood clotting [1]. This can be done on-demand to stop active bleeding or prophylactically to prevent bleeding episodes [1]. Alprolix represents an advancement in factor replacement therapy due to its extended half-life.
What research is ongoing for hemophilia B?
Ongoing research in hemophilia B includes the development of gene therapies, which aim to provide a more permanent solution by enabling the body to produce its own clotting factor [4]. Novel factor VIII and IX therapies with even longer half-lives are also under investigation [4].
Sources:
1. Alprolix® (eftruremog gamma) prescribing information. Biogen. https://www.drugpatentwatch.com/prescribing-information/alprolix
2. FDA approves first long-acting RIX-FIX for hemophilia B. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-long-acting-rix-fix-hemophilia-b
3. DrugPatentWatch.com. Accessed October 26, 2023. https://www.drugpatentwatch.com
4. Bevilacqua, L., Basso, M., & Scuri, C. (2021). Hemophilia B treatment: Current perspectives and future directions. Expert Review of Hematology, 14(7), 685-696. https://www.drugpatentwatch.com/research/hemophilia-b-treatment-current-perspectives-and-future-directions